한빛사논문
- 조회601
Won-Tae Kim1, Kelsey Hennick1, Joshua Johnson1, Brendan Finnerty1, Seunga Choo1, Sarah B Short1, Casey Drubin1, Ryan Forster1, Mary L McMaster2 & Dirk Hockemeyer1,3,4,*
1 Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, CA, USA
2 Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD, USA
3 Chan Zuckerberg Biohub, San Francisco, CA, USA
4 Innovative Genomics Institute, University of California, Berkeley, Berkeley, CA, USA
*Corresponding author.
Abstract
Mutations in the shelterin protein POT1 are associated with chronic lymphocytic leukemia (CLL), Hodgkin lymphoma, angiosarcoma, melanoma, and other cancers. These cancer‐associated POT1 (caPOT1) mutations are generally heterozygous, missense, or nonsense mutations occurring throughout the POT1 reading frame. Cancers with caPOT1 mutations have elongated telomeres and show increased genomic instability, but which of the two phenotypes promotes tumorigenesis is unclear. We tested the effects of CAS9‐engineered caPOT1 mutations in human embryonic and hematopoietic stem cells (hESCs and HSCs, respectively). HSCs with caPOT1 mutations did not show overt telomere damage. In vitro and in vivo competition experiments showed the caPOT1 mutations did not confer a selective disadvantage. Since DNA damage signaling is known to affect the fitness of HSCs, the data argue that caPOT1 mutations do not cause significant telomere damage. Furthermore, hESC lines with caPOT1 mutations showed no detectable telomere damage response while showing consistent telomere elongation. Thus, caPOT1 mutations are likely selected for during cancer progression because of their ability to elongate telomeres and extend the proliferative capacity of the incipient cancer cells.
논문정보
- Research article
- 2021년 05월 (BRIC 등록일 2021-05-18)
- 국외 연구진
- 생명과학 > 노화/암생물학
댓글 작성 로그인
팝업 닫기관련 링크
연구자 키워드
관련분야 연구자보기
소속기관 논문보기
관련분야 논문보기
해당논문 저자보기
